1. Home
  2. INCR vs RNTX Comparison

INCR vs RNTX Comparison

Compare INCR & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.83

Market Cap

47.4M

Sector

Health Care

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.05

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
RNTX
Founded
1994
2001
Country
Israel
United States
Employees
N/A
10
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4M
47.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
INCR
RNTX
Price
$0.83
$1.05
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
39.5K
685.2K
Earning Date
05-01-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.54
N/A
Revenue Next Year
$41.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$1.00
52 Week High
$1.77
$2.22

Technical Indicators

Market Signals
Indicator
INCR
RNTX
Relative Strength Index (RSI) 58.78 31.90
Support Level $0.86 N/A
Resistance Level $0.93 $1.36
Average True Range (ATR) 0.06 0.17
MACD 0.01 -0.09
Stochastic Oscillator 77.33 1.82

Price Performance

Historical Comparison
INCR
RNTX

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: